Three Predictive Oncology Inc. (NASDAQ: POAI) Comp
Post# of 281
(Total Views: 304)
Posted On: 06/24/2021 4:20:37 PM
Three Predictive Oncology Inc. (NASDAQ: POAI) Companies Participate in Popular Biotechnology Innovation Organization Digital Conference
- More than 3,200 pharmaceutical and biotech companies, plus government and academic organizations attended latest BIO Conference
- Predictive Oncology’s Helomics, TumorGenesis, Soluble Biotech all attended the virtual conference from June 14-18, 2021
- Companies leveraged different components of the conference to entertain new partnerships or customers
Every industry has a revolving calendar of events, but some are “must attends” due to their global reach and prospective deal flow, like conferences put on by Biotechnology Innovation Organization, or just “BIO” as it’s known. This year, three wholly owned subsidiaries of Predictive Oncology (NASDAQ: POAI) – Helomics, TumorGenesis and Soluble Biotech – attended BIO DIGITAL, a premier international biotech partnering event held virtually on June 10-11 & 14-18, 2021. The Predictive Oncology companies attended the event during the second leg of the conference.
BIO is the world’s largest advocacy association representing member companies, state biotechnology groups, academic and research institutions, and related organizations across the U.S. and in 30+ countries. This year’s virtual conference attracted more than 3,200 pharmaceutical and biotech companies, in addition to government and academic organizations.
Each year, the BIO events feature presentations from key opinion leaders and some of the world’s brightest scientific minds discussing the latest breakthroughs in medicine. While informative, the thrust of attending for companies like that of Predictive Oncology is networking and one-on-one sessions that can result in new partnerships or customers.
“In previous conferences Soluble Biotech has typically received more than a dozen requests for proposals, leading to new contracts for their main service of providing protein therapeutic formulations (i.e., formulations for vaccines, antibodies, virus-like particles),” said Predictive Oncology CEO J. Melville Engle. He added that the Helomics unit is leveraging BIO’s one-on-one sessions to showcase its precision medicine discovery platform branded “PeDAL” (https://nnw.fm/BuQvg).
PeDAL, an acronym for Patient-centric Drug Discovery using Active Learning, is a unique technology that combines a proprietary, clinically-validated tumor profiling assay, a knowledgebase of proprietary and public data together with active learning. The active learning allows for the efficient exploration of drug responses against a large diverse patient biology “space.”
The conference allowed TumorGenesis to market its products and services specialized on culturing cancer cells from ovarian and breast cancers that more accurately mimic a patient’s tumors. TumorGenesis technology effectively “fools” ovarian cancer cells into growing outside the body, where they can be studied to better understand the efficacy and safety of cancer drugs specific to the patient. These improved ex-vivo tumor models can then be used by researchers to investigate cancer and by clinicians to develop patient-specific treatment plans.
Engle summed up the comprehensiveness of POAI’s divisions in saying, “Our unique approach allows Pharma therapeutic groups to see how we embrace the complexity and diversity of patient tumors in a highly-scalable and efficient experimental exploration of drugs and drug combinations for patient-specific populations.” And, thanks to organizations like BIO, all the companies’ utility and value can be showcased at global scale.
For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- More than 3,200 pharmaceutical and biotech companies, plus government and academic organizations attended latest BIO Conference
- Predictive Oncology’s Helomics, TumorGenesis, Soluble Biotech all attended the virtual conference from June 14-18, 2021
- Companies leveraged different components of the conference to entertain new partnerships or customers
Every industry has a revolving calendar of events, but some are “must attends” due to their global reach and prospective deal flow, like conferences put on by Biotechnology Innovation Organization, or just “BIO” as it’s known. This year, three wholly owned subsidiaries of Predictive Oncology (NASDAQ: POAI) – Helomics, TumorGenesis and Soluble Biotech – attended BIO DIGITAL, a premier international biotech partnering event held virtually on June 10-11 & 14-18, 2021. The Predictive Oncology companies attended the event during the second leg of the conference.
BIO is the world’s largest advocacy association representing member companies, state biotechnology groups, academic and research institutions, and related organizations across the U.S. and in 30+ countries. This year’s virtual conference attracted more than 3,200 pharmaceutical and biotech companies, in addition to government and academic organizations.
Each year, the BIO events feature presentations from key opinion leaders and some of the world’s brightest scientific minds discussing the latest breakthroughs in medicine. While informative, the thrust of attending for companies like that of Predictive Oncology is networking and one-on-one sessions that can result in new partnerships or customers.
“In previous conferences Soluble Biotech has typically received more than a dozen requests for proposals, leading to new contracts for their main service of providing protein therapeutic formulations (i.e., formulations for vaccines, antibodies, virus-like particles),” said Predictive Oncology CEO J. Melville Engle. He added that the Helomics unit is leveraging BIO’s one-on-one sessions to showcase its precision medicine discovery platform branded “PeDAL” (https://nnw.fm/BuQvg).
PeDAL, an acronym for Patient-centric Drug Discovery using Active Learning, is a unique technology that combines a proprietary, clinically-validated tumor profiling assay, a knowledgebase of proprietary and public data together with active learning. The active learning allows for the efficient exploration of drug responses against a large diverse patient biology “space.”
The conference allowed TumorGenesis to market its products and services specialized on culturing cancer cells from ovarian and breast cancers that more accurately mimic a patient’s tumors. TumorGenesis technology effectively “fools” ovarian cancer cells into growing outside the body, where they can be studied to better understand the efficacy and safety of cancer drugs specific to the patient. These improved ex-vivo tumor models can then be used by researchers to investigate cancer and by clinicians to develop patient-specific treatment plans.
Engle summed up the comprehensiveness of POAI’s divisions in saying, “Our unique approach allows Pharma therapeutic groups to see how we embrace the complexity and diversity of patient tumors in a highly-scalable and efficient experimental exploration of drugs and drug combinations for patient-specific populations.” And, thanks to organizations like BIO, all the companies’ utility and value can be showcased at global scale.
For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)